Patents Assigned to NeuPharma, Inc.
  • Substituted quinazolines for inhibiting kinase activity
    Patent number: 11865120
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: February 25, 2022
    Date of Patent: January 9, 2024
    Assignee: NEUPHARMA, INC.
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • Certain chemical entities, compositions, and methods
    Patent number: 11465975
    Abstract: Chemical entities that are kinase inhibitors, their polymorphs, pharmaceutical compositions and methods of treatment of cancer are described herein.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: October 11, 2022
    Assignee: NEUPHARMA, INC
    Inventor: Xiangping Qian
  • Certain chemical entities, compositions, and methods
    Patent number: 11325940
    Abstract: Chemical entities that are novel compounds, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: October 8, 2019
    Date of Patent: May 10, 2022
    Assignee: NEUPHARMA, INC.
    Inventor: Xiangping Qian
  • Substituted quinazolines for inhibiting kinase activity
    Patent number: 11304957
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: April 19, 2022
    Assignee: NEUPHARMA, INC.
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • Certain chemical entities, compositions, and methods
    Patent number: 11208388
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: December 28, 2021
    Assignee: NEUPHARMA, INC
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • Certain chemical entities, compositions, and methods
    Patent number: 10947201
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: February 16, 2016
    Date of Patent: March 16, 2021
    Assignee: NEUPHARMA, INC.
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • Certain chemical entities, compositions, and methods
    Patent number: 10766920
    Abstract: Chemical entities that are novel compounds, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: September 8, 2020
    Assignee: NEUPHARMA, INC.
    Inventor: Xiangping Qian
  • Certain chemical entities, compositions, and methods
    Patent number: 10759766
    Abstract: Chemical entities based on quinoxaline that are kinase inhibitors are described. Specifically, quinoxaline derivatives of Formula I, containing a diarylamide or diarylurea substructure that inhibit Braf mutant kinase activity, pharmaceutical compositions containing the inhibitor compounds and methods of treatment of cancer comprising administering an effective amount of the Braf inhibitor compound are described.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: September 1, 2020
    Assignee: NEUPHARMA, INC.
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • Substituted quinazolines for inhibiting kinase activity
    Patent number: 10653701
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: May 19, 2020
    Assignee: NEUPHARMA, INC.
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • Certain chemical entities, compositions, and methods
    Patent number: 10590106
    Abstract: Chemical entities that are quinoxaline kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: March 17, 2020
    Assignee: NeuPharma, Inc.
    Inventors: Yong-Liang Zhu, Xiangping Qian
  • Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer
    Patent number: 10561652
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of using these chemical entities, e.g., for treatment of cancer are described.
    Type: Grant
    Filed: April 4, 2019
    Date of Patent: February 18, 2020
    Assignee: NEUPHARMA, INC.
    Inventors: Yong-Liang Zhu, Xiangping Qian
  • Certain chemical entities, compositions, and methods
    Patent number: 10544106
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: January 28, 2020
    Assignee: NEUPHARMA, INC.
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • Certain steroids and methods for using the same in the treatment of cancer
    Patent number: 10487108
    Abstract: Chemical entities that are novel compounds, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: November 26, 2019
    Assignee: NEUPHARMA, INC.
    Inventor: Xiangping Qian
  • Certain chemical entities, compositions, and methods
    Patent number: 10457641
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: October 29, 2019
    Assignee: NEUPHARMA, INC.
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • Certain chemical entities, compositions, and methods
    Patent number: 10344048
    Abstract: Chemical entities that are novel compounds, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: July 9, 2019
    Assignee: NEUPHARMA, INC.
    Inventor: Xiangping Qian
  • Substituted quinazolines for inhibiting kinase activity
    Patent number: 10172868
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: January 8, 2019
    Assignee: NEUPHARMA, INC.
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer
    Patent number: 10137125
    Abstract: Benzenesulfonamide derivatives of quinoxaline that are kinase inhibitors, pharmaceutical compositions and methods of using these derivatives, e.g., for treatment of cancer are described.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: November 27, 2018
    Assignee: NEUPHARMA, INC.
    Inventors: Yong-Liang Zhu, Xiangping Qian
  • Certain chemical entities, compositions, and methods
    Patent number: 10065986
    Abstract: Chemical entities that are novel compounds, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: September 4, 2018
    Assignee: NeuPharma, Inc.
    Inventor: Xiangping Qian
  • Certain chemical entities, compositions, and methods
    Patent number: 10065932
    Abstract: Chemical entities based on quinoxaline that are kinase inhibitors are described. Specifically quinoxaline derivatives of Formula I, containing a diarylamide or diarylurea substructure that inhibit Braf mutant kinase activity, pharmaceutical compositions containing the inhibitor compounds and methods of treatment of cancer comprising administering an effective amount of the Braf inhibitor compound are described.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: September 4, 2018
    Assignee: NeuPharma, Inc.
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • Substituted quinoxalines for inhibiting kinase activity
    Patent number: 10047059
    Abstract: Described herein are kinase inhibitors represented by Formula I: pharmaceutical compositions thereof, and uses thereof including but not limited to uses in treatment of cancer.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: August 14, 2018
    Assignee: NeuPharma, Inc.
    Inventors: Xiangping Qian, Yong-liang Zhu